Skip to content

Study · Measured the body's own peptide · 2011

4 results

Interleukin-18-mediated interferon-gamma secretion is regulated by thymosin beta 4 in human NK cells.

Lee HR, Yoon SY, Song SB, Park Y, Kim TS, Kim S, Hur DY, Song HK, Park H, Cho D

Immunobiology13 Apr 2011Cited by 14 (Europe PMC)

PMID21742406 (opens in a new tab)DOI10.1016/j.imbio.2011.04.002 (opens in a new tab)PepBankPUB-21742406
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01LabEndogenous levelIn vitro (cells)Mechanism

    In the human NK cell line NK-92MI, recombinant IL-18 increased the endogenous level of Tβ4 through the p38MAPK and JNK signalling pathway.

    In plain wordsIn human immune cells, IL-18 raised the cells' own thymosin beta‑4 levels.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseEndogenous Tβ4 level after rhIL-18
    Study

    humann: not reported in source

    NK-92MI human NK cell line
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    In this study, recombinant human IL-18 (rhIL-18) enhanced the endogenous level of Tβ4 through p38MAPK and JNK signaling pathway in the human NK cell line, NK-92MI.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

Studies that did not test the peptide alone3

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 02LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism

    Overexpression of endogenous Tβ4 in NK cells stimulated IFN-γ expression and secretion.

    In plain wordsIn human immune cells, making more of their own thymosin beta‑4 increased interferon-gamma output.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseIFN-γ expression and secretion after Tβ4 overexpression
    Study

    humann: not reported in source

    human NK cells
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Overexpression of endogeneous Tβ4 stimulated IFN-γ expression and secretion.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  2. 03LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism

    Pretreatment with an inhibitor for Tβ4 decreased IL-18-enhanced IFN-γ secretion in NK cells.

    In plain wordsIn human immune cells, blocking thymosin beta‑4 reduced the interferon-gamma rise caused by IL-18.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseIL-18-enhanced IFN-γ secretion after Tβ4 inhibitor
    Study

    humann: not reported in source

    human NK cells
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    pretreatment with an inhibitor for Tβ4 decreased IL-18-enhanced IFN-γ secretion

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  3. 04LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism

    Tβ4-specific short hairpin RNA reduced IFN-γ production in primary NK cells and in the human NK cell line.

    In plain wordsIn human immune cells, silencing thymosin beta‑4 reduced interferon-gamma production.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseIFN-γ production after Tβ4 shRNA
    Study

    humann: not reported in source

    NK-92MI cell line and primary NK cells
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    transfection with Tβ4-specific short hairpin RNA resulted in reduction of IFN-γ production in primary NK cells as well as in the human NK cell line

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.